Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Year | Volume (Price x Shares) | Change |
---|---|---|
2024 | $52.06 M | -41.31% |
2023 | $88.71 M | -11.66% |
2022 | $0.10 B | 125.23% |
2021 | $44.58 M | 70.14% |
2020 | $26.2 M | -57.24% |
2019 | $61.28 M | -22.47% |
2018 | $79.04 M | 3.14% |
2017 | $76.63 M | 5.66% |
2016 | $72.53 M | -28.24% |
2015 | $0.10 B | -51.63% |
2014 | $0.20 B | 598.64% |
2013 | $29.9 M |
Company | FTD volume (3months) | FTD volume (1 year) | Country |
---|---|---|---|
Pfizer PFE | $10.32 M | $0.31 B | ๐บ๐ธ USA |
Eli Lilly LLY | $56.64 M | $0.12 B | ๐บ๐ธ USA |
Sanofi SNY | $21.22 M | $52.23 M | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | $0.23 B | $0.32 B | ๐บ๐ธ USA |